ID 1231

HOW DO PATIENTS WITH TYPE 2 DIABETES MELLITUS EVOLVE DURING FOUR YEARS OF FOLLOW-UP IN PRIMARY CARE

PAULA COLACICCHI , PATRICIA POLO BARRERO , ENRIQUE ALARCON PARIENTE , FRANCISCA MUÑOZ COBOS , JOSE MARÍA SANTA CRUZ TALLEDO , LOURDES MARTIN BRAVO

ID 1281

EFFECTIVENESS OF A COMPREHENSIVE CARE PROTOCOL IN TYPE 2 DIABETES MELLITUS AND ASSOCIATED COMORBIDITIES IN PRIMARY CARE

CAROLINA LAPENA ESTELLA, VICENCIA LAGUNA FERNANDEZ , CLARISA DIGON BLANCO , ROSA MARIA AZNAR VILELLA , ENRIQUETA BORRAS GALLART , JOSE LUIS DEL VAL GARCIA

ID 1248

REDUCTION IN CARDIOVASCULAR DEATH WITH EMPAGLIFLOZIN IS CONSISTENT ACROSS CATEGORIES OF BASELINE HBA1C AND CHANGE IN HBA1C: RESULTS FROM EMPA-REG OUTCOME

L NG , DAVID FITCHETT , CHRISTOPH WANNER , UWE HEHNKE , JYOTHIS T. GEORGE , BERNARD ZINMAN

ID 1253

THE IMPACT OF OBESITY IN THE RISK TO DEVELOP TYPE 2 DIABETES AND THE RELATION OF DIET AND GUT MICROBIOTA IN A PREDIABETIC AND ELDERLY POPULATION.

DIANA DÍAZ RIZZOLO , B KOSTOV , M LOPEZ-SILES , M MARTÍNEZ-MEDINA , A SISÓ-ALMIRALL , R GOMIS

ID 1247

EMPAGLIFLOZIN REDUCES MORTALITY AND HOSPITALISATION FOR HEART FAILURE IN PATIENTS WITH OR WITHOUT A HISTORY OF MYOCARDIAL INFARCTION OR STROKE AT BASELINE

L NG , SILVIO E. INZUCCHI , STEVEN SAMBEVSKI , STEFAN KASPERS , EGON PFARR , BERNARD ZINMAN

ID 1277

NASAL GLUCAGON (NG) FOR THE TREATMENT OF MODERATE-TO-SEVERE HYPOGLYCEMIC EPISODES IN REAL-WORLD SETTINGS IN ADULTS WITH TYPE 1 DIABETES (T1D)

ALINA JILETCOVICI

ID 1265

THE PHYSICIANS' CHOICE: SINGLE PILL OR FIXED DOSE COMBINATION?

PÄIVI MARIA PALDANIUS , HELMUT BRATH , GIOVANNI BADER , CHANTAL MATHIEU

ID 1269

CLINICAL PRACTICE AND OUTCOMES VERSUS CLINICAL GUIDELINES: A REAL-WORLD PERSPECTIVE ON THE UPDATED NICE GUIDELINES

PÄIVI MARIA PALDANIUS , VOLKER FOOS , JASON P. GORDON , MARC EVANS , PHIL MCEWAN

ID 1270

NETWORK META-ANALYSIS OF RESPONSES TO DPP-4 AND SGLT2 INHIBITORS: WHAT NEXT AFTER METFORMIN WITH A BASELINE HBA1C ?8%?

PÄIVI MARIA PALDANIUS , WILLIAM DAVID STRAIN , MERLIN CHRISTOPHER THOMAS , JAMES E FOLEY